Abstract
The in vitro chemosensitivities of lymphocytes and bone marrow specimens from hematological cancer patients have been examined. The tests were based on the quantitative immunohistochemical detection of ornithine decarboxylase. Ornithine decarboxylase catalyzes the rate limiting step of the biosynthesis of putrescine, an important member of the naturally occurring polyamines. This enzyme can be regarded as an early marker of proliferation and its presence in drug-treated cells suggests drug resistance, while its disappearance suggests drug-sensitivity. The validity of the concept has been confirmed first by testing the presence of ornithine decarboxylase in cultured cells, followed by testing blood samples from hematological cancer patients. It is conceivable that this in vitro chemosensitivity test can be applied for other malignacies.
| Original language | English |
|---|---|
| Pages (from-to) | 51-56 |
| Number of pages | 6 |
| Journal | International Journal of Medicine, Biology and the Environment |
| Volume | 28 |
| Issue number | 1 |
| State | Published - 2000 |
Keywords
- Anti-cancer drug
- Bone-marrow
- Chemosensitivity
- Immunohistochemistry
- Lymphocytes
- Ornithine decarboxylase
